中度癌痛患者应用曲马多及羟考酮的初始镇痛疗效及安全性研究

The initial analgesic effect and safety of tramadol and oxycodone in patients with moderate cancer pain

目的探讨中度癌痛患者应用曲马多及羟考酮的初始镇痛疗效及安全性研究。方法选择2018年2月-2019年2月我院所收治的共60例中度癌痛患者并将其随机等分为研究组与参照组,研究组共30例给予口服盐酸羟考酮缓释片治疗,参照组共30例给予口服盐酸曲马多缓释片治疗,于治疗1周后对比两组患者的NRS评分(疼痛评分)、不良反应发生率等指标。结果治疗后研究组与参照组的NRS评分值经比较,差异具有统计学意义(P<0.05);治疗后研究组患者的便秘症状发生率低于参照组,差异具有统计学意义(P<0.05);其他例如恶心、呕吐、头疼等不良症状差异无统计学意义(P>0.05)。结论使用盐酸羟考酮缓释片治疗中度癌痛患者的初始阵痛安全性和疗效优于盐酸曲马多缓释片。

Objective To investigate the efficacy and safety of initial analgesia with tramadol and oxycodone in patients with moderate cancer pain.Methods A total of 60 patients with moderate cancer pain admitted to our hospital from February 2018 to February 2019 were randomly divided into study group and reference group.The study group received 30 oral oxycodone sustained-release tablets.For treatment,30 patients in the reference group were treated with oral tramadol hydrochloride sustained-release tablets.After 1 week of treatment,the NRS scores(pain scores)and adverse reaction rates were compared between the two groups.Results After treatment,the NRS scores of the study group and the reference group were compared,the difference was statistically significant(P<0.05).The incidence of constipation symptoms in the study group was significantly lower than that in the reference group after treatment,the difference was statistically significant(P<0.05).other adverse symptoms such as nausea,vomiting,headache,etc.were not statistically significant(P>0.05).Conclusion The safety and efficacy of oxycodone hydrochloride sustained-release tablets in the treatment of patients with moderate cancer pain was significantly better than that of tramadol hydrochloride sustained-release tablets.